AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19809305 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 870
Study 19809305 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated factor XII type A (XIIaA)
Number of subjects: 870
Study 19809305 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of XIIaA and BNP
Number of subjects: 870
Study 19809365 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical blood pressure measurements
Number of subjects: 1130
Study 19809365 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measured blood pressure measurements
Number of subjects: 1130
Study 19809365 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related changes in blood pressure
Number of subjects: 1130
Study 19809365 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic pulse wave velocity
Number of subjects: 1130
Study 19809365 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral pulse wave velocity
Number of subjects: 1130
Study 19809365 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension treatment
Number of subjects: 1130
Study 19811637 — intervention group
Group type: EXPERIMENTAL
Intervention: AS1402 (1-16 mg/kg) administered via intravenous infusion every 1 to 3 weeks until disease progression.
Number of subjects: 26
Study 19811637 — intervention group
Group type: EXPERIMENTAL
Intervention: AS1402 (1-16 mg/kg) administered via intravenous infusion.
Number of subjects: 26
Study 19812047 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial pulmonary vein isolation (PVI) using minimal invasive epicardial off-pump monolateral right-sided video-assisted thoracic surgery (VATS) with UltraCinch and high-intensity focused ultrasound (HIFU)
Number of subjects: 15
Study 19812047 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial pulmonary vein isolation (PVI)
Number of subjects: 15
Study 19812176 — intervention group
Group type: EXPERIMENTAL
Intervention: High omega-3 LCPUFA intake (median: 0.11% of total energy intake)
Number of subjects: 1837
Study 19812383 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan (10 mg/kg)/fludarabine (180 mg/m(2))-based reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation
Number of subjects: 103
Study 19812461 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine at a target dose of 20 mg daily for 26 weeks
Number of subjects: 43
Study 19813252 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler ultrasonography (TCD)
Number of subjects: 192
Study 19816190 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional autologous lymphokine-activated killer (LAK) cells
Number of subjects: 33
Study 19816190 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher numbers of CD3+/CD16+/CD56+ (T-LAK) cells in the cell products
Number of subjects: 33
Study 19816412 — intervention group
Group type: EXPERIMENTAL
Intervention: Rating of perceived exertion (RPE) during submaximal aerobic exercise task
Number of subjects: 113
Study 19816412 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological exertion during submaximal aerobic exercise task
Number of subjects: 113
Study 19816412 — intervention group
Group type: EXPERIMENTAL
Intervention: Average weight regain after 1 year
Number of subjects: 113
Study 19816674 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased proportion of small adipose cells
Number of subjects: 49
Study 19816674 — intervention group
Group type: EXPERIMENTAL
Intervention: Size of mature adipose cells
Number of subjects: 49
Study 19816674 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance
Number of subjects: 49
Study 19816674 — intervention group
Group type: EXPERIMENTAL
Intervention: Small adipose cells
Number of subjects: 49
Study 19817748 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat 100 or 200 mg administered twice daily for 14 consecutive days followed by a 1-week rest interval.
Number of subjects: 10
Study 19817748 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat 200 mg
Number of subjects: 10
Study 19818257 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ziprasidone
Number of subjects: 0
Study 19820236 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative antithrombin (AT) activity on postoperative days (PODs) 2 and 3
Number of subjects: 1403
Study 19820236 — intervention group
Group type: COMPARATOR
Intervention: Preoperative antithrombin (AT) activity
Number of subjects: 1403
Study 19820236 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of MACE
Number of subjects: 1403
Study 19820552 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (ESC) plus bupropion (BUP), rapid dose escalation to ESC 40 mg/day plus BUP 400 to 450 mg/day by study day 15
Number of subjects: 49
Study 19820783 — intervention group
Group type: EXPERIMENTAL
Intervention: Infectious uveitis group
Number of subjects: 25
Study 19820783 — intervention group
Group type: COMPARATOR
Intervention: Noninfectious uveitis group
Number of subjects: 25
Study 19821755 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System (CGMS)
Number of subjects: 16
Study 19822591 — intervention group
Group type: EXPERIMENTAL
Intervention: Purchases made in corner stores before and after school
Number of subjects: 833
Study 19822798 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 0
Study 19822798 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 19822896 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 73
Study 19825163 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait patterns (males)
Number of subjects: 134
Study 19825163 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait patterns (females)
Number of subjects: 134
Study 19825163 — intervention group
Group type: EXPERIMENTAL
Intervention: WOMAC questionnaire (females)
Number of subjects: 134
Study 19825163 — intervention group
Group type: EXPERIMENTAL
Intervention: WOMAC questionnaire (males)
Number of subjects: 134
Study 19825163 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 health survey (females)
Number of subjects: 134
Study 19825163 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 health survey (males)
Number of subjects: 134
Study 19828038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine plus lifestyle changes
Number of subjects: 10929
Study 19828038 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 10929
Study 19828712 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acid (SFA) diet
Number of subjects: 20
Study 19828712 — intervention group
Group type: COMPARATOR
Intervention: Monounsaturated fatty acid (MUFA) diet
Number of subjects: 20
Study 19828714 — intervention group
Group type: EXPERIMENTAL
Intervention: White men
Number of subjects: 1967
Study 19828714 — intervention group
Group type: EXPERIMENTAL
Intervention: White women
Number of subjects: 1967
Study 19828714 — intervention group
Group type: COMPARATOR
Intervention: African American men
Number of subjects: 1967
Study 19828714 — intervention group
Group type: COMPARATOR
Intervention: African American women
Number of subjects: 1967
Study 19828715 — intervention group
Group type: EXPERIMENTAL
Intervention: C3 polymorphism rs11569562 GG homozygotes
Number of subjects: 1754
Study 19828715 — intervention group
Group type: EXPERIMENTAL
Intervention: C3 polymorphism rs2250656 AA homozygotes
Number of subjects: 1754
Study 19829297 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg +/-20% s.c. b.i.d.)
Number of subjects: 15
Study 19833304 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine administered by intravenous infusion (140 microg/kg/min) to obtain hyperemic flow profiles.
Number of subjects: 183
Study 19833304 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a history of DM (n = 22).
Number of subjects: 183
Study 19833304 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with newly diagnosed DM (n = 39).
Number of subjects: 183
Study 19833304 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with abnormal glucose tolerance (n = 58).
Number of subjects: 183
Study 19833304 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with normal glucose tolerance (n = 62).
Number of subjects: 183
Study 19833304 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed DM and a history of DM as predictors of CFR <2.
Number of subjects: 183
Study 19833304 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance.
Number of subjects: 183
Study 19833408 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal microscopy patterns of reticular nevi
Number of subjects: 53
Study 19833408 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal microscopy patterns of globular nevi
Number of subjects: 53
Study 19833408 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal microscopy patterns of cobblestone nevi
Number of subjects: 53
Study 19833408 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal follow-up study
Number of subjects: 53
Study 19833408 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal follow-up of globular nevi
Number of subjects: 53
Study 19833996 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatherers of information (female, parents, emotional support providers)
Number of subjects: 183
Study 19833996 — intervention group
Group type: EXPERIMENTAL
Intervention: Disseminators (female first- and second-degree relatives, older or same generation family members, those with a cancer history, emotional or tangible support providers)
Number of subjects: 183
Study 19833996 — intervention group
Group type: EXPERIMENTAL
Intervention: Blockers (spouses or partners, male first-degree relatives)
Number of subjects: 183
Study 19834799 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 0
Study 19835828 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted A/Indonesia/5/2005 vaccine (single booster dose)
Number of subjects: 315
Study 19835828 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted A/Vietnam/1194/2004 vaccine (primed 14 months earlier)
Number of subjects: 315
Study 19835828 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted A/Vietnam/1194/2004 vaccine (primed 14 months earlier, two booster doses)
Number of subjects: 315
Study 19835828 — intervention group
Group type: COMPARATOR
Intervention: Un-primed control group (two doses of adjuvanted vaccine)
Number of subjects: 315
Study 19837768 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FMT
Number of subjects: 98
Study 19837768 — intervention group
Group type: COMPARATOR
Intervention: (18)F-FDG
Number of subjects: 98
Study 19837914 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese relative GH deficient (GHD)
Number of subjects: 102
Study 19837914 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese GH sufficient (GHS)
Number of subjects: 102
Study 19837914 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight subjects
Number of subjects: 102
Study 19837930 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion at 0.25 pmol x kg(-1) x min(-1) on day 1 and day 3
Number of subjects: 10
Study 19837930 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion on day 1 and day 3
Number of subjects: 10
Study 19837930 — intervention group
Group type: COMPARATOR
Intervention: Saline control on day 2
Number of subjects: 10
Study 19837930 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion in healthy controls on day 1
Number of subjects: 10
Study 19837930 — intervention group
Group type: COMPARATOR
Intervention: Saline control in healthy controls on day 2
Number of subjects: 10
Study 19838106 — intervention group
Group type: EXPERIMENTAL
Intervention: IOUS-guided finger compression for demarcation of resection area
Number of subjects: 33
Study 19838774 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab therapy
Number of subjects: 25
Study 19838774 — intervention group
Group type: COMPARATOR
Intervention: Rituximab therapy with co-treatment
Number of subjects: 25
Study 19841398 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse-grit microdermabrasion
Number of subjects: 40
Study 19841398 — intervention group
Group type: COMPARATOR
Intervention: Medium-grit microdermabrasion
Number of subjects: 40
Study 19843703 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted diabetes lifestyle intervention
Number of subjects: 0
Study 19843887 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiliximab (375 mg/m² or 500 mg/m²) combined with fludarabine, cyclophosphamide, and rituximab (FCR) for 6 cycles
Number of subjects: 31
Study 19843887 — intervention group
Group type: COMPARATOR
Intervention: FCR alone (control group, not explicitly detailed in the abstract)
Number of subjects: 31
Study 19843899 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 acid ethyl esters (2 g/d, containing 930 mg EPA and 750 mg DHA)
Number of subjects: 122
Study 19843899 — intervention group
Group type: COMPARATOR
Intervention: Corn oil placebo capsules
Number of subjects: 122
Study 19843899 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 acid ethyl esters
Number of subjects: 122
Study 19843914 — intervention group
Group type: EXPERIMENTAL
Intervention: Low AT/AF burden (<5.5 hours)
Number of subjects: 2486
Study 19843914 — intervention group
Group type: EXPERIMENTAL
Intervention: High AT/AF burden (≥5.5 hours)
Number of subjects: 2486
Study 19843914 — intervention group
Group type: COMPARATOR
Intervention: Zero AT/AF burden
Number of subjects: 2486
Study 19843914 — intervention group
Group type: COMPARATOR
Intervention: Comparison of low vs zero burden
Number of subjects: 2486
Study 19843914 — intervention group
Group type: COMPARATOR
Intervention: Comparison of high vs zero burden
Number of subjects: 2486
Study 19845088 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic psychotherapy with transference interpretations
Number of subjects: 1
Study 19845588 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT with [(18)F]FDG labeling of islets
Number of subjects: 5
Study 19846066 — intervention group
Group type: EXPERIMENTAL
Intervention: TA-CD vaccine (82 microg, n = 4; 360 microg, n = 6) administered at weeks 1, 3, 5, and 9
Number of subjects: 10
Study 19846066 — intervention group
Group type: COMPARATOR
Intervention: Cocaine (0 mg, 25 mg, 50 mg)
Number of subjects: 10
Study 19846634 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex PCR
Number of subjects: 263
Study 19846634 — intervention group
Group type: COMPARATOR
Intervention: Blood culture
Number of subjects: 263
Study 19846634 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex PCR and Blood culture
Number of subjects: 263
Study 19846730 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 2 diastolic dysfunction
Number of subjects: 305
Study 19846730 — intervention group
Group type: EXPERIMENTAL
Intervention: LA volume index >32 mL/m(2)
Number of subjects: 305
Study 19846730 — intervention group
Group type: EXPERIMENTAL
Intervention: Summed stress score on myocardial perfusion scintigraphy
Number of subjects: 305
Study 19846730 — intervention group
Group type: EXPERIMENTAL
Intervention: Valvulo-arterial impedance
Number of subjects: 305
Study 19846730 — intervention group
Group type: EXPERIMENTAL
Intervention: Summed stress score
Number of subjects: 305
Study 19847907 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 19849892 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 30
Study 19850249 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination-facilitated PCI (abciximab plus half-dose reteplase)
Number of subjects: 2452
Study 19850249 — intervention group
Group type: COMPARATOR
Intervention: Abciximab alone
Number of subjects: 2452
Study 19850249 — intervention group
Group type: COMPARATOR
Intervention: Spoke site alone (no facilitated PCI)
Number of subjects: 2452
Study 19850258 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute stent
Number of subjects: 139
Study 19850694 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human TSH (rhTSH)
Number of subjects: 51
Study 19850694 — intervention group
Group type: COMPARATOR
Intervention: Thyroid hormone withdrawal (L-T4)
Number of subjects: 51
Study 19850844 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with dry eye syndrome (including Sjögren's syndrome)
Number of subjects: 33
Study 19850844 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 33
Study 19850844 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Sjögren's syndrome
Number of subjects: 33
Study 19850844 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with dry eye syndrome
Number of subjects: 33
Study 19850844 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCL10 levels
Number of subjects: 33
Study 19850844 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCL11 levels
Number of subjects: 33
Study 19851652 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive AKI (+) group
Number of subjects: 817
Study 19851652 — intervention group
Group type: COMPARATOR
Intervention: Negative AKI (-) group
Number of subjects: 817
Study 19852906 — intervention group
Group type: EXPERIMENTAL
Intervention: Predrafting personal factors (behavioral assessment, cognitive assessment, linguistic ability, and education)
Number of subjects: 2362
Study 19852906 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive functioning, education, rank, and position during the trauma
Number of subjects: 2362
Study 19852906 — intervention group
Group type: EXPERIMENTAL
Intervention: Predrafting psychological assessment of social and individual qualifications
Number of subjects: 2362
Study 19852906 — intervention group
Group type: COMPARATOR
Intervention: Behavioral assessment
Number of subjects: 2362
Study 19852906 — intervention group
Group type: COMPARATOR
Intervention: Training
Number of subjects: 2362
Study 19852963 — intervention group
Group type: EXPERIMENTAL
Intervention: Des-gamma-carboxy prothrombin (DCP) at month 0 with cutoff of 40 mAU/mL
Number of subjects: 39
Study 19852963 — intervention group
Group type: EXPERIMENTAL
Intervention: Des-gamma-carboxy prothrombin (DCP) at month 0 with cutoff of 150 mAU/mL
Number of subjects: 39
Study 19852963 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-fetoprotein (AFP) at month 0 with cutoff of 20 ng/mL
Number of subjects: 39
Study 19852963 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-fetoprotein (AFP) at month 0 with cutoff of 200 ng/mL
Number of subjects: 39
Study 19852963 — intervention group
Group type: EXPERIMENTAL
Intervention: Des-gamma-carboxy prothrombin (DCP) at month -12 with low cutoff
Number of subjects: 39
Study 19852963 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-fetoprotein (AFP) at month -12 with low cutoff
Number of subjects: 39
Study 19852963 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of DCP and AFP
Number of subjects: 39
Study 19852963 — intervention group
Group type: COMPARATOR
Intervention: Surveillance ultrasound
Number of subjects: 39
Study 19852963 — intervention group
Group type: COMPARATOR
Intervention: Doubling of AFP
Number of subjects: 39
Study 19852963 — intervention group
Group type: COMPARATOR
Intervention: Combination of tests
Number of subjects: 39
Study 19853693 — intervention group
Group type: COMPARATOR
Intervention: TIMI flow 3 post-PCI
Number of subjects: 1018
Study 19853693 — intervention group
Group type: COMPARATOR
Intervention: TMPG 2/3 post-PCI
Number of subjects: 1018
Study 19853693 — intervention group
Group type: COMPARATOR
Intervention: Residual ST elevation <2 mm
Number of subjects: 1018
Study 19853693 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI TMPG 2/3
Number of subjects: 1018
Study 19853837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic intervention at workstation
Number of subjects: 200
Study 19853837 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 19854499 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV2-hRPE65v2 gene therapy (1.5 x 10(10) vector genomes, 4.8 x 10(10) vector genomes, 1.5 x 10(11) vector genomes)
Number of subjects: 12
Study 19854499 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV2-hRPE65v2 gene therapy
Number of subjects: 12
Study 19854509 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy water ((2)H(2)O) labelling for 6 weeks
Number of subjects: 29
Study 19854509 — intervention group
Group type: EXPERIMENTAL
Intervention: RosetteSep-based method for CLL cell isolation
Number of subjects: 29
Study 19854509 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy water ((2)H(2)O) labelling
Number of subjects: 29
Study 19855289 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost/timolol fixed combination
Number of subjects: 0
Study 19855289 — intervention group
Group type: COMPARATOR
Intervention: Bimatoprost
Number of subjects: 0
Study 19855289 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 0
Study 19856395 — intervention group
Group type: EXPERIMENTAL
Intervention: Study medication adherence (MedAd)
Number of subjects: 191
Study 19856395 — intervention group
Group type: EXPERIMENTAL
Intervention: Study visit adherence (VAd)
Number of subjects: 191
Study 19856395 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence during dose titration
Number of subjects: 191
Study 19856395 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic status (SES) influence on adherence
Number of subjects: 191
Study 19857703 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart transplantation for light patients (below 80 kg)
Number of subjects: 658
Study 19857703 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart transplantation for heavy patients (80 kg or above)
Number of subjects: 658
Study 19857703 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting time for light patients (below 80 kg)
Number of subjects: 658
Study 19857703 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting time for heavy patients (80 kg or above)
Number of subjects: 658
Study 19857703 — intervention group
Group type: EXPERIMENTAL
Intervention: Deaths before transplantation for light patients (below 80 kg)
Number of subjects: 658
Study 19857703 — intervention group
Group type: EXPERIMENTAL
Intervention: Deaths before transplantation for heavy patients (80 kg or above)
Number of subjects: 658
Study 19857703 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors related to not receiving a heart transplant
Number of subjects: 658
Study 19857702 — intervention group
Group type: EXPERIMENTAL
Intervention: NTproBNP
Number of subjects: 658
Study 19857702 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP
Number of subjects: 658